Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014070 (encephalomyelitis)
 13,017 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system mediated by CD4+ T cells reactive with myelin basic protein (MBP). Rats were rendered resistant to the induction of EAE by vaccination with synthetic peptides corresponding to idiotypic determinants of the beta chain VDJ region and J alpha regions of the T cell receptor (TCR) that are conserved among encephalitogenic T cells. These findings demonstrate the utility of TCR peptide vaccination for modulating the activity of autoreactive T cells and represent a general therapeutic approach for T cell-mediated pathogenesis.
 ...
PMID:Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. 281 89

Spirogermanium (SG) is a metal-containing compound reported to have antitumor, antiarthritic, antimalarial and immunoregulatory activity. In this study we have demonstrated that treatment of mice and rats with spirogermanium results in an inhibition of autoimmune disease and cell-mediated immune (CMI) responses. Prophylactic administration of SG inhibited the development of adjuvant-induced arthritis and the DTH response to purified protein derivative (PPD) in Lewis strain rats. SG treatment was also able to alleviate the symptoms of experimental autoimmune encephalomyelitis (EAE) induced in Lewis rats. In two strains of mice, BDF1 and C57B1/6, the DTH response to sheep red blood cells could be suppressed by intraperitoneal (i.p.) administration of SG. The spleens of both mice and rats that have been treated with this drug contain suppressor cells which inhibit the response of normal cells to concanavalin A (Con A) and the mixed lymphocyte reaction. In addition, the generation of cytotoxic T cells (CTL) in the murine MLR is abrogated in the presence of these suppressor cells. The suppressor cells were radiation-resistant (2000 rad), indomethacin-insensitive and were not depleted by treatment with anti-Thy-1.2 antiserum plus complement. These results suggest that SG modulates cell-mediated immune responses in vivo by the induction of non-specific suppressor cells.
 ...
PMID:Immunomodulatory activity and non-specific suppressor cell generation by spirogermanium in murine and rat models of cell-mediated immunity. 297 35

Japanese encephalitis and postmeasles encephalomyelitis represent two important forms of acute encephalitis in the developing world. Japanese encephalitis accounts for 20,000 acute illnesses per year, and measles encephalomyelitis accounts for as many as 100,000. Both are accompanied by mortalities of 20%-30%, and in both forms, approximately one-half of the survivors have neurological sequelae. Therefore, these two diseases are responsible for a considerable proportion of worldwide mental and motor disabilities. Furthermore, both diseases are preventable with use of safe vaccines. Despite these similarities, their very different pathologies appear to be based on different mechanisms of pathogenesis (table 2). In Japanese encephalitis there is direct invasion of the virus into the nervous system, selective infection and destruction of neurons, and evidence that both humoral and cellular immune responses attenuate the infection. In measles encephalomyelitis there is little evidence that the virus invades the nervous system. Rather, measles virus infects lymphoid cells and causes abnormalities in immune regulation. Humoral immune responses are not found within the nervous system, and the cellular immune response may be inappropriately directed against host antigens. In measles encephalomyelitis, the inflammatory cells entering the nervous system may be the effector cells of autoimmune disease.
 ...
PMID:The pathogenesis of acute viral encephalitis and postinfectious encephalomyelitis. 302 98

We found that the course of the chemiluminescence activity (CL-A) of peripheral blood monocytes of Lewis rats with acute experimental autoimmune encephalomyelitis (EAE) correlates well with the clinical course of this autoimmune disease and that only a reduction in T helper cells caused a reduction in CL-A. However, in multiple sclerosis (MS) patients the CL-A increased when clinical improvement started. The serum of these patients contained at least two stimulatory substances. More than 50% of the stimulatory effect could be blocked by antibodies to interferon-gamma.
 ...
PMID:The significance of the inflammatory reactions for the development of clinical signs in multiple sclerosis and acute experimental autoimmune encephalomyelitis as assessed by means of the spontaneous chemiluminescence activity of peripheral blood monocytes. 314 41

Experimental Allergic Encephalomyelitis (EAE) was induced in rhesus monkeys by subcutaneous immunization with calfbrain homogenate in complete Freunds adjuvant. Monkeys were treated with major histocompatibility complex (MHC) Class II specific monoclonal antibodies (MoAb) as soon as the first clinical EAE signs became apparent. Two different treatments were tested. One consisted of 10 daily injections of a mixture of two MHC Class II specific MoAb, reactive with a monomorphic structure of rhesus monkey Class II molecules. The other consisted of 10 daily injections of Genox3.53, specific for HLA-DQW1. This MoAb crossreacts well with monkeys and also detects a polymorphism in this species and is presumably reactive with the RhLA-DQW1 antigen. Both MoAb treatments could modify the clinical course of EAE favourably. Untreated animals invariably died within 3 d of the onset of clinical EAE signs. Only one of the three monkeys treated with the monomorphic MHC Class II MoAb preparation died within 3 d, and the other two survived significantly longer than untreated animals. Both animals treated with Genox3.53 survived significantly longer than untreated control animals. Although only a few animals were tested, these results clearly show the possible beneficial influence of MHC Class II specific MoAb on a T-cell mediated autoimmune disease.
 ...
PMID:Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies. 325 83

Experimental allergic encephalomyelitis (EAE) in Lewis rats is an acute monophasic autoimmune disease. It can be treated prophylactically and therapeutically with high doses of cyclosporin A (CsA). Here we demonstrate that low-dose CsA does not prevent a first attack of EAE, but, on the contrary, induces a chronic relapsing form of the disease in 100% of Lewis rats examined. Possible explanations for the high relapse rate after low-dose CsA treatment are discussed. Further studies will be needed to evaluate the immunological mechanisms responsible for these results.
 ...
PMID:Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. 325 96

Autoimmune diseases are experimental models of human demyelinating diseases such as multiple sclerosis and idiopathic polyneuritis: experimental auto-immune encephalomyelitis (EAE) and experimental autoimmune neuritis. Demyelinating lesions occurring in chronic EAE could be due to the action of autoantibodies rather than to a cellular action involving lymphokines. An antibody-dependent cellular myelinotoxicity could also be the mechanism responsible for demyelination; these mechanisms are suggested by in vitro and in vivo demyelination experiments and by the presence of demyelinating autoantibodies against component(s) of myelin in EAE area. The demyelinating mechanisms could be the same in multiple sclerosis. However, they have not been proven so far.
 ...
PMID:[Demyelination and autoimmunity]. 329 94

Allele-specific monoclonal anti-I-A antibodies are capable of specifically suppressing the immune response to antigens under the control of the allele towards which the antibody is directed, without suppressing the response to antigens under the control of the alternative allele of the I-A alpha and beta chain genes in an F1 heterozygote. This phenomenon, which has been termed 'allele-specific immunosuppression', is antigen-specific, long-lasting and transferrable with Thy-1-positive spleen cells. This type of immunosuppression has been applied to animal models of autoimmune disease, in both homozygous and heterozygous animal models. Anti-I-A monoclonal antibodies are capable of preventing, suppressing and treating experimental allergic encephalomyelitis (EAE), of partially suppressing experimental autoimmune myasthenia gravis, and of preventing the onset of type I insulin-dependent diabetes in the BB/W diabetic rat. In addition, this type of immunotherapy has succeeded in almost completely suppressing nephritis in NZB X NZW F1 mice, which normally develop severe lupus-like nephritis. Significant toxicity, which may be due to anti-allotype antibodies, anti-idiotype antibodies, or to impurities in the monoclonal antibody preparations, has been encountered in the BB/W diabetic rat. In addition, attempts to extend these observations to EAE in the cynomolgus monkey have encountered significant mortality which appears to be attributable to the monoclonal antibody injections (anti-HLA-DR). The mechanism of this toxicity and means of circumventing it are currently under investigation. These results demonstrate the critical role of I-A molecules in the induction and continuance of the autoimmune process in these experimental animal models.
 ...
PMID:Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease. 331 1

An antigen non-specific suppressor factor (SF4) produced by a permanent mouse T cell line inhibits the mitogen- and antigen-induced proliferation of cells in vitro. The suppression of immune response is not restricted by interspecies barrier. Administration of the SF4 factor in vivo had a significant suppressive effect on the induction and manifestation of experimental allergic encephalomyelitis (EAE) in rats. Rats treated with SF4 factor, the first dose being injected on the day of EAE induction, had no clinical manifestations or developed only mild clinical signs of EAE. Administration of the SF4 starting on day 4 after EAE induction, when the immune system had been activated, depressed the course of EAE. The results obtained in this model autoimmune disease indicate that the described suppressor factor is active in vivo and that it may be used to depress the autoaggressive immune reactions.
 ...
PMID:Suppression of experimental allergic encephalomyelitis in rats by suppressor factor from a permanent T cell line. 348 25

The central role of T lymphocytes in the initiation, regulation and propagation of autoimmune diseases defines them as most suitable targets for selective immunotherapy. The recent advance in culturing human and animal T cell lines allows us to select monoclonal antibodies specific for differentiation antigens expressed by activated T lymphocytes. We selected a monoclonal antibody cytotoxic for a subpopulation of activated rat T cells. In vivo, this antibody effectively blocks immune responses to foreign antigens or autoantigen and prevents development of autoimmune diseases like experimental allergic encephalomyelitis and adjuvant arthritis. Even already established disease can be blocked by a single injection of antibody. Furthermore, this monoclonal antibody can be used to monitor the course of autoimmune disease progression from peripheral blood samples.
 ...
PMID:Therapy of rat autoimmune disease by a monoclonal antibody specific for T lymphoblasts. 349 Nov 49


<< Previous 1 2 3 4 5 6 7 8 9 10